폐질환 치료제의 효율적인 신약개발을 위한 생체표지자 및 대리결과 변수 = Biomarkers and Surrogate Endpoints for Development of New Drug on Pulmonary Disease

다국어 초록 (Multilingual Abstract)

Biomarkers are likely to be important in the study of various pulmonary diseases for many reasons. Research efforts in developing biomarkers and surrogate endpoints of lung diseases have resulted in the identification of new risk factors and novel drug targets, as well as the establishment of treatment guidelines. Government agencies, academic research institutions, diagnostic industries, and pharmaceutical companies all recognize the importance of biomarkers in new drug development and advancing therapies to improve public health. In drug development, biomarkers are used to evaluate early signals of efficacy and safety, to select dose, and to identify the target population. Identification of suitable end points not only would help investigators design appropriate clinical trials but would assist clinicians in caring for this patient population. Though the area of pulmonology has received much attention in the past decades, it still lags behind with regard to the development of biomarkers, particularly those of health effects and susceptibility. This review critically summarized several biomarker researches such as Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) study with objectives of identifying the parameters that predict disease progression of COPD, as well as biomarkers that may serve as surrogate end-points.

참고문헌 (Reference)

1 이철주, "바이오마커 연구개발 동향 한국생화학분자생물학회"

2 성수현, "당뇨병 및 골다공증 치료제의 효율적인 신약개발을 위한 생체표지자 및 대리 결과 변수의 역할 및 활용" 대한약학회 52 (52): 331-344, 2008

3 Revision of Committee, "ritical path opportunities reports"

4 Kostikas, K, "pH in expired breath condensate of patients with inflammatory airway disease" 165 : 1364-, 2002

5 Cazzola, M, "on behalf of the American Thoracic Society/European Respiratory Society Task Force on outcomes of COPD : Outcomes for COPD pharmacological trials: from lung function to biomarkers" 31 : 416-, 2008

6 Lee, J. W, "Validation of assays for the bioanalysis of novel biomarkers:Practical recommendations for clinical investigation of new drug entities" 132 : 119-, 2003

7 Rolan, P, "Use of biomarkers from drug discovery through clinical practice: Report of the ninth European federation of pharmaceutical sciences conference on optimizing drug development" 73 (73): 284-, 2003

8 Lesko, L. J, "Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies" 41 : 347-, 2001

9 Rasp, G, "Tryptase in nasal fluid is a useful marker of allergic rhinitis" 48 (48): 72-, 1993

10 Matsuzaki, K, "Transforming growth factorbeta during carcinogenesis: the shift from epithelial to mesenchymal signaling" 41 : 295-, 2006

11 Lezcano-Meza, D, "The monocyte-derived chemokine is released in the bronchoalveolar lavage fluid of steady-state asthmatics" 58 : 1125-, 2003

12 Rolan, P, "The contribution of clinical pharmacology surrogates and models to drug development-a critical appraisal" 44 : 219-, 1997

13 Snell, N, "The clinical utility of biomarkers in asthma and COPD" 8 : 222-, 2008

14 Lazarus, R, "TOLL-like receptor 10 genetic variation is associated with asthma in two independent samples" 170 : 594-, 2004

15 Francis, J. N, "T lymphocytes expressing CCR3 are increased in allergic rhinitis compared with non-allergic controls and following allergen immunotherapy" 62 : 59-, 2007

16 Malo, O, "Systemic inflammation during exacerbations of chronic obstructive pulmonary disease" 38 : 172-, 2002

17 Hurst, J. R, "Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease" 173 : 71-, 2006

18 Twaddell, S, "Surrogate outcome markers in research and clinical practice" 32 : 47-, 2009

19 Kline, J. A, "Surrogate markers for adverse outcomes in normotensive patients with pulmonary embolism" 34 (34): 2773-, 2006

20 Brightling, C. E, "Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease" 60 : 193-, 2005

21 Brightling, C. E, "Sputum eosinophilia and short-term response to proednisolone in chronic obstructive pulmonary disease: a randomised controlled trial" 356 : 1480-, 2000

22 Sagel, S. D, "Sputum biomarkers of inflammation in cystic fibrosis lung disease" 4 : 406-, 2007

23 Kucher, N, "Risk stratification of acute pulmonary embolism" 32 : 838-, 2006

24 Kharitonov, S. A, "Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children" 21 : 433-, 2003

25 Borrill, Z, "Reproducibility of exhaled breath condensate pH in chronic obstructive pulmonary disease" 25 : 269-, 2005

26 Russell, R. E, "Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease" 26 : 602-, 2002

27 Gibson, P, "Relationship between induced sputum eosinophils and the clinical pattern of childhood asthma" 58 : 116-, 2003

28 Gutierrez, V, "Relationship between induced sputum cell counts and fluid-phase eosinophil cationic protein and clinical of physiologic profiles in mild asthma" 82 : 559-, 1999

29 Yariktas, M, "Relationship between Toxocara seropositivity and allergic rhinitis" 21 : 248-, 2007

30 Broekhuizen, R, "Raised CRP levels mark metabolic and functional impairment in advanced COPD" 61 : 17-, 2006

31 Torbicki, A, "Pulmonary embolism: role of echocardiography and of biological markers" 6 (6): 805-, 2005

32 Sekine, I, "Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer" 10 : 731-, 1999

33 Kucher, N, "Prognostic role of brain natriuretic peptide in acute pulmonary embolism" 107 : 2545-, 2003

34 Kerem, E, "Prediction of mortality in patients with cystic fibrosis" 326 : 1187-, 1992

35 Revision Committee, "Post-genomic biomarker" 12 (12): 2004

36 Tateno, H, "Plasma eotaxin level and severity of asthma treated with corticosteroid" 98 : 782-, 2004

37 Kostikas, K, "Oxidative stress in expired breath condensate of patients with COPD" 124 : 2003

38 Kinnula, V. L, "Oxidant-antioxidant imbalance as a potential contributor to the progression of human pulmonary fibrosis" 10 (10): 727-, 2008

39 Colburn, W. A, "Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development" 40 : 1419-, 2000

40 Jatakanon, A, "Neutrophilic inflammation in severe persistent asthma" 160 : 1532-, 1999

41 Fang, S.-Y, "Neuropeptide innervations and neuroendocrine cells in allergic rhinitis and chronic hypertrophic rhinitis" 28 : 228-, 1998

42 Kalayci, O, "Monocyte chemotactic protein-4 (MCP-4; CCL-13):A biomarker of asthma" 41 : 27-, 2004

43 Jaffer, F. A, "Molecular imaging of cardiovascular disease" 116 : 1052-, 2007

44 Stanski, D. R, "Model-based drug development: A critical path opportunity" FDA 2006

45 Danhof, M, "Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers" 22 (22): 1432-, 2005

46 de Raucourt, E, "Markers of hemostatic system activation in pulmonary embolism. Changes during and after cessation of anticoagulant treatment" 11 (11): 249-, 2000

47 Panzner, P, "Marked up-regulation of T lymphocytes and expression of interleukin-9 in bronchial biopsies from patients with chronic bronchitis with obstruction" 124 : 1909-, 2003

48 Santamaria, F, "Lung structure abnormalities, but normal lung function in pediatric bronchiectasis" 130 : 480-, 2006

49 in’t Veen, J, "Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal" 160 : 93-, 1999

50 Kucher, N, "Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism" 107 : 1576-, 2003

51 Vernooy, J. H, "Local and systemic inflammation in patients with chronic obstructive pulmonary disease" 166 : 1218-, 2002

52 Kostikas, K, "Leukotriene B4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma" 127 : 1553-, 2005

53 Pesci, A, "Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease" 12 : 380-, 1998

54 O’Shaughnessy, T. C, "Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1" 155 : 852-, 1997

55 Tzanakis, N, "Induced sputum CD8+ T-lymphocyte subpopulations in chronic obstructive pulmonary disease" 98 : 57-, 2004

56 Nguyen, L. T, "Increased resting energy expenditure is related to plasma TNF-alpha concentration in stable COPD patients" 18 : 269-, 1999

57 Corradi, M, "Increased nitrosothiols in exhaled breath condensate in inflammatory airway disease" 163 : 854-, 2001

58 Leung, T, "Increased macrophage-derived chemokine in exhaled breath condensate and plasma from children with asthma" 34 : 786-, 2004

59 Biernacki, W. A, "Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD" 58 : 294-, 2003

60 Saetta, M, "Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic onstructive pulmonary disease" 165 : 1404-, 2002

61 Lamkhioued, B, "Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation" 159 : 4593-, 1997

62 Dekhuijzen, P. N, "Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease" 154 : 813-, 1996

63 Vila, S, "Importance of serum interleukin-6 as a mediator of systemic inflammation in patients with alpha-1 antitrypsin deficiency" 38 : 263-, 2002

64 Culpitt, S. V, "Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease" 167 : 24-, 2003

65 Brody, A. S, "High-resolution computed tomography of the chest in children with cystic fibrosis:support for use as an outcome surrogate" 29 : 731-, 1999

66 Bucchioni, E, "High levels of interleukin-6 in the exhaled breath condensate of patients with COPD" 97 : 1299-, 2003

67 Suraokar, M. B, "High expression of epithelial-mesenchymal transition (EMT) markers in malignant mesothelioma and possible therapeutic intervention using an N-cadherin antagonist" 2008

68 Aaron, S. E, "Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease" 163 : 349-, 2001

69 Lee, J. W, "Fit-for-purpose method development and validation for successful biomarker measurement" 23 (23): 312-, 2006

70 Cardinale, F, "Exhaled nitric oxide, total serum IgE and allergic sensitization in childhood asthma and allergic rhinitis" 16 : 236-, 2005

71 Turner, S, "Exhaled nitric oxide in the diagnosis and management of asthma" 8 : 70-, 2008

72 Zeidler, M, "Exhaled nitric oxide in the assessment of asthma" 10 : 31-, 2003

73 Montuschi, P, "Exhaled leukotrienes and prostaglandins in asthma" 109 : 615-, 2002

74 Carpagnano, G. E, "Exhaled interleukin-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys)" 505 : 169-, 2004

75 Paredi, P, "Exhaled ethane, a marker of lipid peroxidation,is elevated in chronic obstructive pulmonary disease" 162 : 369-, 2000

76 Montuschi, P, "Exhaled carbon monoxide and nitric oxide in COPD" 120 : 496-, 2001

77 Henriksen, A. H, "Exhaled and nasal NO level in allergic rhinitis: relation to sensitization, pollen season and bronchial hyperresponsiveness" 13 : 301-, 1999

78 Montuschi, P, "Exhaled 8-isoprostane an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers" 162 : 1175-, 2000

79 Vestbo, J, "Evaluation of COPD longitudinally to identify predictive surrogate end-points" 31 : 869-, 2008

80 Harrison, A, "Evaluation and management of the acutely dyspneic patient: the role of biomarkers" 23 : 371-, 2005

81 Liu, L, "Enhanced generation of helper T type 1 and 2 chemokines in allergen-induced aasthma" 169 : 1118-, 2004

82 Kalenderian, R, "Elevated histamine and tryptase levels in smokers’ bronchoalveolar lavage fluid. Do lung mast cells contribute to smokers’ emphysema?" 94 : 119-, 1988

83 Strieter, R. M, "Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis" 170 : 133-, 2004

84 Woosley, R. L, "Drug development and the FDA’s critical path initiative" 81 (81): 129-, 2007

85 Yamabuki, T, "Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas" 67 (67): 2517-, 2007

86 Keatings, V. M, "Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma" 153 : 530-, 1996

87 Baraldi, E, "Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations" 58 : 505-, 2003

88 Obase, Y, "Correlation between airway hyperresponsiveness and airway inflammation in a young adult population: eosinophil, ECP, and cytokine levels in induced sputum" 86 : 304-, 2001

89 Brody, A. S, "Computed tomography in the evaluation of cystic fibrosis lung disease" 172 : 1246-, 2005

90 Wark, P, "Clinical usefulness of inflammatory markers in asthma" 2 : 11-, 2003

91 Frank, R, "Clinical biomarkers in drug discovery and development" 2 : 566-, 2003

92 Tonnel, A, "Characteristics of the inflammatory response in bronchial lavage fluids from patients with status asthmaticus" 124 : 267-, 2001

93 Pin, I, "Changes in the cellular profile of induced sputum after allergen-induced asthmatic responses" 145 : 1265-, 1992

94 Revision of Committee, "Challenge and Opportunity on the critical path to new medical product"

95 Saetta, M, "Cellular and structural bases of chronic obstructive pulmonary disease" 163 : 1304-, 2001

96 Kucher, N, "Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism" 108 : 2191-, 2003

97 Pilette, C, "CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge" 23 : 876-, 2004

98 Itillie-Leblond, I, "CC chemokines and interleukin-5 in bronchial lavage fluid from patients with status asthmaticus. Potential implication in eosinophil recruitment" 162 : 586-, 2000

99 Pinto-Plata, V. M, "C-reactive protein in patients with COPD, control smokers and non-smokers" 61 : 23-, 2006

100 Kharitonov, S. A, "Biomarkers of some pulmonary diseases in exhaled breath" 7 : 1-, 2002

101 Soehne, M, "Biomarkers in pulmonary embolism" 19 : 558-, 2004

102 Colburn, W. A, "Biomarkers in drug discovery and development: From target identification through drug marketing" 43 : 329-, 2003

103 Zeisberg, M, "Biomarkers for epithelialmesenchymal transitions" 119 : 1429-, 2009

104 Biomarkers Definition Working Group, "Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework" 69 (69): 89-, 2001

105 Wagner, J. A, "Biomarker validation and qualification: Fitness for use"

106 Park, S, "Association of interleukin-5 and eotaxin with acute exacerbation of asthma" 131 : 283-, 2003

107 Gan, W. Q, "Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metaanalysis" 59 : 574-, 2004

108 Di Franco, A, "Analysis of sputum cell counts during spontaneous moderate exacerbations of asthma in comparison to the stable phase" 20 : 155-, 2003

109 Montuschi, P, "Analysis of exhaled breath condensate for monitoring airway inflammation" 23 : 232-, 2002

110 Grumelli, S, "An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema" 1 : 8-, 2004

111 Corradi, M, "Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary disease" 167 : 1380-, 2003

112 Yamamoto, C, "Airway inflammation in COPD assessed by sputum levels of interleukin-8" 112 : 505-, 1997

113 Donaldson, G. C, "Airway and systemic inflammation and decline in lung function in patients with COPD" 128 : 1995-, 2005

114 Nel, A. E, "Acute phase response in bronchiectasis and bronchus carcinoma" 47 : 196-, 1985

115 Saetta, M, "Activated Tlymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis" 147 : 301-, 1993

116 "ATS/ERS Rcommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide" 171 : 912-, 2005

117 Boot, J, "A critical appraisal of methods used in early clinical development of novel drugs for the treatment of asthma" 20 : 201-, 2007

118 Abdel-Rahman, A, "A comparative study of two angiogenic facters: vascular endothelial growth factor and angiogenin in induced sputum from asthmatic children in acute attack" 129 : 266-, 2006